Massive Bio Featured in Two Categories on CB Insights’ AI Drug R&D Market Map
Massive Bio, one of the leaders in AI-powered oncology patient recruitment and clinical trial matching, has been named in two pivotal categories on CB Insights’ latest AI Drug Research & Development Market Map. This recognition underscores Massive Bio’s innovative contributions to revolutionising cancer care through advanced artificial intelligence solutions. CB Insights’ market map highlights companies […]
TLS and The Ohio State University Collaborate to Develop Boron Precision Cancer Therapy
In a groundbreaking advancement for precision oncology, TAE Life Sciences (TLS) announced on May 3rd, the signing of a Letter of Intent to collaborate with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) in the development and evaluation of novel boron-based […]
Veristat Appoints Gabriela Rosu, M.D., as Senior Director of Global Medical Affairs Team
Veristat, the Science-First Full Service CRO and Consultancy announced that Gabriela Rosu, M.D., has joined as Senior Director of Global Medical Affairs. Dr Rosu is a seasoned professional with over twenty years of experience in scientific and clinical fields, having significantly contributed to the planning and execution of pivotal activities that have led to the approval […]
ICPO Foundation and SBMN announce a strategic partnership
The International Centers for Precision Oncology (ICPO) Foundation and the Brazilian Society of Nuclear Medicine (SBMN) today announced a collaboration to advance the field of Radiomolecular Precision Oncology (RPO) in Brazil. This collaboration is aimed at deploying the ICPO Academy for Theranostics and later establishing ICPO Centers in Brazil and contribute to the global advancements […]
Molecular Partners and Orano Med collaborate to develop novel Radio-DARPin therapeutics
Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Orano Med, a pioneer in targeted alpha therapy, have announced a collaboration to develop novel Radio-DARPin therapeutics (RDTs) that use Orano Med’s 212Pb radioisotope as a payload to selectively kill cancer cells. Both companies will leverage their […]
